Trials / Recruiting
RecruitingNCT06655246
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 157 (estimated)
- Sponsor
- Kura Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Gastrointestinal Stromal Cancer
- Gastrointestinal Stromal Neoplasm
- Gastrointestinal Stromal Tumor, Malignant
- Gastrointestinal Stromal Cell Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ziftomenib | menin inhibitor |
| DRUG | imatinib mesylate | kinase inhibitor |
Timeline
- Start date
- 2025-03-27
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
- First posted
- 2024-10-23
- Last updated
- 2026-02-05
Locations
32 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06655246. Inclusion in this directory is not an endorsement.